Back to today’s briefing

Story perspectives

EMA Unveils New Guidelines to Streamline Drug Modifications

9/23/2025

45 8

Summary

Story summary

The European Medicines Agency (EMA) announced Variations Guidelines on Sept. 22, 2025 to streamline modifications to drug marketing authorizations.
The guidelines aim to improve lifecycle management and reflect advances in development; EMA will require MA holders to report variations by health impact, Type IA, IB, II.
New procedures detailing these guidelines will be published in December 2025.

1 of 1

Story summary

The European Medicines Agency (EMA) announced Variations Guidelines on Sept. 22, 2025 to streamline modifications to drug marketing authorizations.
The guidelines aim to improve lifecycle management and reflect advances in development; EMA will require MA holders to report variations by health impact, Type IA, IB, II.
New procedures detailing these guidelines will be published in December 2025.